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Abstract: There is a high demand for new drugs against malaria, which takes millions of lives annually. The abuse of classical antimalar-
ials from the late 1940’s to the early 1980’s has bred resistant parasites, which led to the use of more potent drugs that ended up by refu-
eling the resistance cycle. An example is chloroquine, once highly effective but now virtually useless against malaria. 
Structure-based rational drug design relies on high-resolution target structures to allow for screening of selective ligands/inhibitors. For 
the past two decades, and especially after the unveiling of the Plasmodium falciparum genome in 2002, enzymes of this lethal malaria 
parasite species have been increasingly attracting the attention of Medicinal Chemists worldwide as promising drug targets. There is par-
ticular emphasis on proteases having key roles on the degradation of host’s hemoglobin within the food vacuole of blood-stage parasites, 
as these depend on such process for their survival. Among such enzymes, Plasmepsins (aspartic proteases) and, especially, Falcipains 
(cysteine proteases) are highly promising antimalarial drug targets. The present review will focus on the computational approaches made 
so far towards the unraveling of the structure, function and inhibition of Falcipains that, by virtue of their quite specific features, are ex-
cellent targets for highly selective inhibitors. 
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1. INTRODUCTION 
Malaria is one of the earliest known diseases. Indeed, what 
would be afterward named malaria has been noted for more than 
4000 years, being the first symptoms described in ancient Chinese 
medical writings [1]. Later, Hippocrates, the “Father of Medicine”, 
also described the manifestations of malaria, and related them to the 
time of year and to where the patients lived [2]. But, the true cause 
of the disease became clear first in 1880, when the French re-
searcher Laveran (Nobel Prize in Medicine 1907) discovered the 
malaria parasite in human blood [3]. In 1897 [4], the English physi-
cian Ross (Nobel Prize in Medicine 1902) and, in 1898 [5], the 
Italian zoologist Grassi, demonstrated that the parasite was injected 
into the human bloodstream through the bite of an infected female 
mosquito [6]. 
Today, malaria remains one of the most important infections in 
human, being the most widespread and severe tropical disease [7]. 
It is mostly present in Africa, Asia and South America and affects 
huge numbers of people: up to 300 million clinical cases, mainly 
children, emerge each year causing near 1 million deaths [8]. The 
five different species that cause human malaria are: Plasmodium 
(P.) vivax, P. malariae, P. ovale, P. falciparum (Pf, the deadliest) 
and P. knowlesi (recently found to infect humans) [9]. 
Several organized efforts to control the transmission and eradi-
cate the disease have been made through history [10]. Two main 
approaches have been employed: killing the parasite and killing the 
parasite vector. Also, various attempts to develop antimalarial vac-
cines can be added to the arsenal of control efforts [11]. These ef-
forts achieved a regional elimination in Southern Europe and in 
some countries in North Africa and in the Middle East. Despite 
initial success, there was a complete failure to eradicate malaria in 
many countries due to a number of factors. Since then, we have 
been witnessing to a massive 2-3 fold increase in occurrences glob-
ally [12, 13]. 
Complex life cycle, disease spreading through a mosquito vec-
tor, resistance of the mosquito to insecticides and a rapidly growing  
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resistance of the malaria parasite to the available drugs are the ma-
jor reasons behind malaria being such a burden to humanity [14-
16]. The parasite is developing new ways of escaping drugs, such as 
antifolates and chloroquine, which was by far the most frequently 
used antimalarial for half a century [17-19], by random mutations 
[20]. Thus, the existing drugs become less effective against their 
targets and finally completely useless against some strains. Al-
though drug combinations including potent antimalarials such as 
artemisinin and its derivatives [21-23], have been effective, there is 
an urgent need to identify new therapeutic targets and to develop 
drugs aimed at such targets.  
For the past two decades, and especially after the unveiling of 
the Plasmodium falciparum genome in 2002 [24], new potential 
drug targets for inhibitor development research have been proposed 
[25, 26]. Among these, falcipains (cysteine proteases) from P. fal-
ciparum are highly promising target enzymes, which play a key role 
in hemoglobin degradation in trophozoites [27-29]. In this article, 
we will review the main characteristics of falcipains, their protein 
inhibitors, their mode of action and structural aspects, with a special 
focus on the advances of computational approaches employed in the 
development of falcipain inhibitors. 
2. ANTIMALARIAL THERAPY 
Understanding the interplay of the malaria parasite with its cel-
lular host provides the biological basis for attempting the con-
trol/eradication of this epidemic. The complete life cycle of malaria 
parasites consists of two basic cycles, an asexual cycle in the hu-
man host and a sexual cycle in the mosquito host [30]. In the former 
situation, the asexual cycle can be further divided into a liver stage 
(or a pre-erythrocytic stage) and an erythrocytic stage [30]. A 
schematic representation of the transmission cycle of this parasite 
appears in (Fig. 1). 
Infection begins when sporozoites are injected into the blood 
stream from the salivary glands of mosquitoes when they bite the 
human host for their blood meal. The sporozoites then travel to the 
liver and invade hepatocytes, where they are converted, through an 
asexual transformation, to trophozoites, which in turn divide into 
several schizonts, eventually generating merozoites. After being 
multiplied in huge numbers, these merozoites rupture the hepato-
cytes and are released into the blood stream, where they invade red 
blood cells (RBC), initiating the erythrocytic stage. This stage is 
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generally similar to the liver stage, in the sense that parasite’s mul-
tiplication in RBC involves formation of merozoites that multiply 
through a second phase of asexual replication, resulting in the pro-
duction of more merozoites that are released from infected RBC to 
invade new ones. This process is repeated over and over again and 
is responsible for the symptomatic phase of malaria. Sometimes, 
during this endo-erythrocytic stage, other forms of the parasite 
emerge as gametocytes, sexually differentiated forms that, when 
taken up by a feeding mosquito, will complete the sexual cycle 
within the mosquito gut until new sporozoites are formed and mi-
grate to the insect’s salivary glands, for a next round in the spread-
ing of infection. 
Though the complex life cycle of the malaria parasite is behind 
the many difficulties felt in suppressing the disease, it offers several 
possible alternatives for the control of infection. One of them is 
mosquito eradication through extensive use of insecticides and 
habitat transformations as, e.g., use of bed nets. This would be, 
probably, the most desirable method, but its successful implementa-
tion is extremely difficult due to the large areas involved, not to 
mention the development of insecticide-resistant mosquito strains. 
Alternatively, the human host can be immunized against the malaria 
parasite through vaccines. Several possible vaccines have been 
under development, mainly focused on the pre-erythrocytic stage. 
Although some projects are particularly promising in this area [32, 
33], a functional vaccine is not available yet and there are no pros-
pects for becoming available soon [34]. So, drug therapy remains 
the mainstay of treatment and prevention of this disease. 
The discovery of drugs to combat malaria has to a large extent 
been serendipitous, and the mechanism of action of many agents is 
still partially or totally unknown. Available antimalarials target 
mainly blood-stage parasites. Chloroquine (Fig. 2) and other qui-
nine alkaloid derivatives have been the XXth century drugs in most 
parts of malaria-endemic regions of the world. Chloroquine appears 
to act by blocking the biocrystallization of heme, while mechanisms 
for related drugs, including quinine, are unknown. Antifolate drugs, 
such as pyrimethamine (Fig. 2), another large and classical group of 
antimalarials, inhibit folate metabolism. Some general antibiotics 
have also been found to exhibit antimalarial activity [19, 21, 35, 
36]. 
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Fig. (2). Molecular structures of pyrimethanine, artemisinim and chloro-
quine. 
During the last decades, a new type of antimalarials based on 
the artemisinin scaffold (Fig. 2) has emerged. These molecules have 
been found to effectively reduce parasitemia but their mechanisms 
of action still remain unknown. Unfortunately, parasite resistance is 
rendering previous antimalarial medicines ineffective in most parts 
of the world. This resistance to antimalarial drugs arises as a result 
of spontaneously occurring mutations that affect the structure and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The life cycle of Plasmodium falciparum, where a and b represent the asexual cycle in human host and the sexual cycle in the mosquito, respectively. 
Figure reprinted from ref. [31] with permission from Elsevier. 
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activity at the molecular level of the drug target in the malaria para-
site or affect the access of the drug to that target [37]. To date, 
clinically relevant resistance has emerged towards all classes of 
antimalarial drugs except for the artemisinins [16]. Despite not 
having been encountered resistance to artemisinin-based antimalar-
ials in the field yet, prominent reports have recently noted delayed 
parasite clearance suggestive of decreased drug sensitivity in 
Southeast Asia [38-40]. 
Early diagnosis and prompt treatment are fundamental compo-
nents of the WHO global strategy for malarial control [41]. Also, 
combination therapy of the effective antimalarial drugs available, 
such as artemisinin and its analogues, is thought to be essential for 
preserving the efficacy of antimalarials and prolonging their useful 
therapeutic life [41, 42]. Therefore, there is unanimity that substan-
tial scientific effort should be devoted to the discovery of additional 
novel therapeutic targets in order to develop new and effective 
antimalarials. 
Since the unveiling of the P. falciparum genome in 2002 [24], a 
number of potential targets for drug intervention have emerged [19, 
43, 44] (Table 1). These potential antimalarial drug targets can be 
broadly classified into three categories, according to their function 
in the parasite’s life cycle [25, 45]: i) targets involved in macromo-
lecular and metabolite synthesis, ii) targets engaged in membrane 
transport and signaling, and iii) targets involved in hemoglobin 
degradation. 
Despite the existence of several potential targets, the present re-
view is particularly focused on inhibition of falcipains, which be-
long to the cysteine protease family of P. falciparum and are in-
volved in hemoglobin metabolism, for which an extensive amount 
of results was already published in the literature. 
2.1. Hemoglobin Metabolism 
Hemoglobin is the most abundant protein in erythrocytes, and 
becomes completely degraded after parasite entry. During the eryth-
rocytic stage, the parasite uses host hemoglobin as a food source 
[59, 60]. Given that Plasmodia have limited capacity for de novo 
amino acid biosynthesis, it has been suggested that hemoglobin 
degradation products are essential for the parasite’s own protein 
biosynthesis, therefore, for its survival. Amino acids from hemo-
globin proteolysis also appear to be required for energy metabolism 
[60] and several studies have proven hemoglobin metabolism to be 
essential for parasite survival [61, 62]. In order for this degradation 
to occur, hemoglobin is initially transported to the parasite’s acidic 
food vacuole where it expresses a number of active proteases [63] 
ready to proceed to this degradation.  
The spectrum of proteolytic activity in the malarial parasite can 
be divided into two functional groups: i) proteases that are involved 
in invasion and rupture of erythrocytes and ii) proteases that are 
involved in hemoglobin hydrolysis [64]. Relative to the later, there 
are two relevant protease families: aspartic proteases and cysteine 
proteases, called plasmepsins and falcipains, respectively.  
The degradation process appears to follow an ordered pathway 
[65, 66], which is outlined in Fig. (3). It has been difficult to deter-
mine whether a plasmepsin or falcipain catalyzes the initial cleav-
age [67]. However, it has been suggested that an initial cleavage 
between Phe33 and Leu34 in the hinge region, of the domain re-
sponsible for holding together the oxygen bound tetramer, unravels 
hemoglobin to expose it to further cleavage [66, 68]. Subsequent 
cleavage into smaller peptides is catalyzed by both plasmepsins and 
falcipains [69]. The metalloprotease falcilysin and dipeptidyl amin-
opeptidase-1 (DPAP1) cleave the resulting small peptides to even 
shorter oligopeptides [65, 70] that are finally hydrolised to free 
amino acids by aminopeptidases [71]. 
During the hemoglobin degradation process, free heme is re-
leased and oxidized from the ferrous (Fe+2) state to the ferric (Fe
+3
) 
hematin [69]. Both heme and hematin are potentially toxic to the 
parasite [72]. To counter this, the parasite has evolved a detoxifica-
tion system resulting in the formation of -hemozoin pigment, an 
inert crystalline hematin polymer [69, 73]. 
From the above, it is understandable that plasmepsins and falci-
pains, proteases that play vital roles in the erythrocytic cycle of 
malaria parasites, have generated substantial interest [74]. Inhibitors 
of these enzymes have been shown to block the hydrolysis of he-
moglobin [75] and to inhibit the rupture of erythrocytes [76], thus 
suggesting that they are valuable candidate therapeutic targets [28, 
77, 78] in the development of new antimalarials. 
3. FALCIPAIN CYSTEINE PROTEASES 
Cysteine proteases were given this name due to the function of 
a catalytic cysteine. This amino acid catalyzes protein hydrolysis 
via nucleophilic attack to the carbonyl carbon of a susceptible bond. 
Falcipains are the best characterized cysteine proteases of the ma-
laria parasite. For instance, analysis of the P. falciparum genome 
sequence suggested the existence of a family of four falcipains: 
Table 1. Summary of Some Novel Targets in P. falciparum with Candidate Inhibitors Currently Under Investigation 
 
Enzyme’s function Enzyme / receptor Candidate inhibitor Refs 
5-enolpyruvyl shhikimate 3-phosphate synthase  Glyphosate  [44] 
Phospholipid biosynthesis G25 [46] 
DOXP reductoisomerase Fosmidomycin [47] 
ACCase Acryloxy phenoxy propionate [48] 
Fab A/Z NAS-21, NAS-91 [49] 
FabH Thiolactomycin [50] 
FabI Triclosan [51] 
HGPRT Immucilin-H [52] 
Macromolecular and metabolite  
synthesis 
Cytochrome c oxidoreductase Atovaquone [53] 
Folate-biopterin transporters Methotrexate, probenecid [54] 
Membrane transport and signaling 
Hexose transporter O-3-hexose derivatives [55] 
Plasmepsins, falcipains Leupeptin, pepstatin and several other compounds [56, 57] 
Hemoglobin degradation 
Hemozoin Triacyl carbinol and several other compounds [58] 
DOXP: 1-deoxy-D-xylulose-5-phosphate; ACCase: acetyl-CoA carboxylase; FabA/Z: -hydroxy acyl-ACP dehydratase; FabH: 3-ketoacyl-ACP synthase III; FabI: enoyl-ACP 
reductase; HGPRT: hypoxanthine-guanine-xanthine phosphoribosyltransferase. 
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falcipain-1 (FP1), falcipain-2 (FP2), falcipain-2’ (FP2’) and falci-
pain-3 (FP3) [29, 79-81]. FP1 is encoded on chromosome 14 and is 
distantly related to the other falcipains in terms of sequence (<40% 
amino acid identity) and function [82]. Its exact physiological role 
has yet to be elucidated. However, some studies suggested that FP1 
could be important in oocyst production during parasite develop-
ment in the mosquito midgut [83] and also could help in the inva-
sion of the host cell by P. falciparum [84, 85]. FP2, FP2’ and FP3, 
encoded within a 12,5 kb stretch of chromosome 11, are closely 
related and appear to be the key hemoglobinases in the acidic food 
vacuole [29, 86]. Also, they are believed to be involved in the trans-
formation of pro-plasmepsins into the mature active enzymes [87]. 
Falcipain-2 is the best studied among this family of cysteine prote-
ases [28]. FP2’ is thought to arise by gene duplication. It presents a 
93% amino acid similarity with FP2 [86], hence suggesting possible 
physiological role as hemoglobinase [81, 88]. FP2 and FP3 present 
a high similarity in sequence (68% identity), share similar sized 
prodomains and include an unusual amino-terminal extension of the 
catalytic domain that is not found in FP1 [28]. Studies with recom-
binant proteins suggested that these proteases are synthesized as 
integral membrane proteins, and subsequently hydrolyzed to release 
soluble active proteases [80]. Both require a reducing environment 
and acidic pH for optimal activity. However, for FP3, it appears 
that hydrolysis is delayed until it enters an acidic environment. At 
acidic pH, FP3 is more active and stable, presenting a higher activ-
ity against native hemoglobin than FP2 [28]. It has been discovered 
that, despite the concentration of FP2 in trophozoites being 1.8 
times that of FP3, the latter seems to cleave hemoglobin about 
twice as rapidly as the former. This indicates that the relative con-
tribution of the two enzymes to hemoglobin degradation is essen-
tially equivalent [80]. Also, another study revealed that the loss of 
FP2 is probably compensated by the increased expression of FP2’ 
and/or FP3, thus suggesting the overlapping functions performed by 
the falcipains [79]. These findings suggest that drug development 
focused on falcipains must take into account simultaneous inhibi-
tion of all the essential falcipains. Nonetheless, given the yet un-
veiled role of FP1 and the apparent equivalence of FP2 to FP2’, it is 
of common sense that a potent inhibitor against both FP2 and FP3 
will most probably impair hemoglobin degradation to levels that are 
lethal for the parasite. Therefore, the present review will be focused 
exclusively on falcipain-2 and falcipain-3. 
3.1. Falcipain Structure and Specificity 
The falcipains are all fairly typical papain-family cysteine pro-
teases, though they have some rather uncommon features, e.g. ex-
ceptionally large prodomains, predicted membrane spanning se-
quences within the prodomains, an unusual insertion between 
highly conserved residues near the carboxy terminus [29, 80] and 
an additional disulfide bond required for their proteolytic activity 
[89]. A feature that falcipains share with other papain-family cys-
teine proteases is the ability of small peptides from the prodomain 
of FP2/3 to become potent inhibitors of these enzymes [90, 91]. 
Furthermore, falcipains also adopt the classical papain-like fold in 
which the protease is divided into L (left) and R (right) domains 
(Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Representation in new cartoon of the structure of falcipain-2 (PDB 
code: 3BPF) with the L domain (Left) and the R (Right) domain colored in 
light grey. The N-terminal extension (FPnose) at the most right and the C-
terminal insertion (FParm) at the bottom are colored in dark grey. Adapted 
from [92]. 
Homology models and X-ray crystallography studies on falci-
pains provided important structural information about these en-
zymes. FP2 and FP3 are single polypeptide chains of 241 and 243 
amino acids, respectively. The catalytic residues CYS42, HIS174 
and ASN204 for FP2 and CYS44, HIS176 and ASN206 for FP3 are 
located at the junction between domains L and R. The catalytic site 
is formed by a cysteine and a histidine, whose side chains form a 
thiolate/imidazolium ion pair, and also by an asparagine, which has 
a crucial role in the appropriate orientation of the ion pair [93]. A 
schematic representation of the mechanism of action is outlined in 
Fig. (5). 
One of the key events in the catalytic hydrolysis of hemoglobin 
is the nucleophilic attack of the thiolate anion to the appropriate 
electron deficient carbonyl group of the substrate. This 1,2-addition 
leads to a negatively charged tetrahedral intermediate that was 
found to be stabilized by the “oxyanion hole” formed by the side 
chains of GLN36 and TRP206, in FP2, and by GLN38 and TRP208 
in FP3. Schechter and Berger [94] have established a nomenclature 
to designate substrate residues and the corresponding enzyme sub-
sites, based on their positions relative to the scissile amide bond 
(Fig. 6). Substrate residues (P) in the direction from the scissile 
bond towards the C-terminal are denoted primed, while residues in 
the N-terminal direction are nonprimed. The same notation is also 
applied to the enzyme subsites (S), or pockets, occupied by the 
substrate. 
The active site of falcipains (Fig. 7) is generally formed by four 
pockets: S1, S2, S1’ and S3 [95]. The S1 pocket is the least defined 
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Fig. (3). The degradation process of hemoglobin in the P. falciparum food vacuole. 
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of the four grooves and, usually, includes the glutamine of the 
“oxyanion hole”. The most well-defined pocket is S2, which seems 
to govern specificity towards FP2 and/or FP3, and to prefer sub-
strates bearing a LEU in the corresponding P2 site [29, 80]. The S1’ 
pocket contains a highly conserved tryptophan, which is known to 
participate in hydrophobic interactions with substrates. Finally, a 
glycine-rich region of the binding site represents the S3 groove.  
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Fig. (6). Schechter and Berger’s nomenclature for substrate residues (P) and 
their corresponding binding sites (S). 
Of interest, FP2 and FP3 structures contain two unique features 
assigned as FP2/3nose and FP2/3arm [92] (Fig. 4). The FP2/3nose mo-
tif, situated at the N-terminus, is required for folding, while the 
FP2/3arm contains a C-terminal insertion and mediates interaction 
between the falcipains and hemoglobin independent of the en-
zyme’s active site [92]. 
3.2. Falcipain Inhibitors: Potential Antimalarial Drugs 
During the last two decades, we have witnessed an impressive 
scientific effort to discover new targets for antimalarial therapy, and 
among them, the falcipain family proteases, namely FP2 and FP3, 
have been defined as promising drug targets [28, 60]. Indeed, most 
studies in this area have shown that falcipain inhibitors prevent 
hemoglobin hydrolysis, block parasite development and cure mur-
ine malaria [75, 78, 96-99]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Representation of the falcipain-3 catalytic site surface showing the 
S1, S1’, S2 and S3 pockets. 
To date, many compounds have been identified as inhibitors of 
falcipains, which are able to block the enzyme’s activity by forming 
a reversible or irreversible covalent bond with the active site cys-
teine. These falcipain inhibitors can be broadly divided into three 
categories [57]: i) peptide-based inhibitors, ii) peptidomimetic in-
hibitors and iii) nonpeptidic inhibitors. Most of the falcipain inhibi-
tors identified so far are peptide-based inhibitors [57] (Fig. 8). This 
category includes peptidyl fluoromethyl ketones [100], peptidyl 
vinyl sulfones [101, 102], peptidyl aldehydes and -ketoamide 
derivatives [103], epoxysuccinyl derivatives [104] and peptidyl 
azirines [105]. Peptidyl aldehydes and -ketoamides inhibit FPs in 
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Fig. (5). Schematic reaction mechanism of the cysteine protease mediated cleavage of a peptide bond. 
1560    Current Medicinal Chemistry,  2011 Vol. 18, No. 10 Teixeira et al. 
a reversible manner, while the others are irreversible inhibitors. 
These classes of compounds were found to inhibit enzymatic activ-
ity of FPs at very low nanomolar range. However, their utility as 
therapeutic agents is limited for their susceptibility to protease deg-
radation and their poor absorption through cell membranes [57]. 
A common strategy to avoid the therapeutic limitations of pep-
tide-based inhibitors is to lock a defined conformation of the pep-
tide into a rigid scaffold. This strategy yielded the peptidomimetic 
FPs inhibitors (Fig. 9), including compounds based on 1,4-
benzodiazepine [106] and pyridone ring [107] scaffolds, which are 
able to reversibly block the enzyme. As far as nonpeptide FP inhibi-
tors are concerned (Fig. 9), these include chalcones [108], which 
are biosynthetic precursors of flavonoids, isoquinolines [95, 96] and 
thiosemicarbazones [109]. 
Historically, novel enzyme inhibitors are discovered either by 
serendipity or by screening of natural and synthetic compounds. 
Over the past few years, through a better understanding of bio-
chemical processes and the emergence of powerful computational 
tools, rational drug design has emerged complementarily to these 
techniques. The advances on computational approaches towards the 
development of novel falcipain inhibitors are reviewed in the fol-
lowing section. 
4. CHEMOINFORMATICS AND MODELING STUDIES OF 
FALCIPAINS AND INHIBITORS 
Nowadays, molecular modeling is considered as a field related 
to the use of diverse strategies, e.g. construction of 3D protein 
structures by homology modeling, analysis of 3D databases, diver-
sity analysis, docking of ligands or continuum methods, for model-
ing and deducing information of a system at the atomic level. Iden-
tification of molecular groups involved in the interaction(s) of a 
chemical moiety or entity with a specific receptor helps to under-
stand the molecular mechanism(s) responsible for their specific 
biological activities. Consequently, acquired knowledge is then 
applied to design new active molecules that can be successfully 
used as bioactive compounds. Among other factors, simulation 
accuracy is limited to the precision of the constructed models. 
When possible, computational simulations have to be compared 
with experimental results for confirmation of the model correctness 
and, if necessary, gathered information is used to modify the mod-
els for obtaining better representations of the system. Other factors 
governing the accuracy of the simulations are related with the com-
putational approach used to compute interesting properties of the 
model system, e.g. interaction energies, structures, etc., which turns 
the field of molecular modeling quite broad and varied. A summary 
of the molecular modeling tools commonly employed in drug de-
velopment will be given in the forthcoming sections. 
4.1. Overview of Computational Methods in Drug Development 
The computer simulation techniques can be broadly classified 
into three main areas: molecular mechanics, molecular dynamics 
and quantum mechanics. The latter technique is subdivided into two 
main categories, semi-empirical molecular orbital methods and ab-
initio calculations. The most accurate approach is the ab-initio 
method, which calculates properties of a system from first princi-
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Fig. (8). Molecular structures of some peptide-based falcipain inhibitors. 
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ples by solving Schrödinger equations numerically. In this method, 
all electrons are treated explicitly and the interactions between at-
oms are determined solely from their electronic configurations and 
position of the atoms. While highly accurate, this method is very 
expensive and can only realistically be implemented for small sized 
systems and very short time scales when applied to molecular dy-
namics. In the semi-empirical methods, various simplifications are 
used, e.g. only treating the valence electrons explicitly and fitting 
several parameters to experimental data (or in some cases to data 
calculated ab-initio), which allows them to probe larger system 
sizes and longer time scales compared to ab-initio methods. Since 
electrons are considered in semi-empirical and ab-initio ap-
proaches, they may be used to investigate processes that involve 
bond breaking/formation and electronic rearrangement.  
The molecular mechanics (MM) approach is used for simula-
tions of very large systems, typically of up to hundreds of thou-
sands of particles. In this approximation, the microscopic state of 
the system can be determined using only the positions and forces 
acting on the atoms. The interaction between atoms is modeled 
using interatomic potentials (force field) derived from either highly 
accurate ab-initio calculations or fitted to experimental data. When 
applied to MD, the MM approach enables the study of systems in a 
time scale up to a microsecond. It is possible to calculate thermo-
dynamic and transport properties and to study a wide range of proc-
esses, such as interactions of molecules with surfaces, phase transi-
tions, and protein dynamics. For even larger systems, the molecular 
mechanics approach is further simplified by introducing restrictions 
to the degree of freedom and treating groups of atoms as contiguous 
units. This method is referred to as mesoscale modeling, and is very 
efficient in accessing quite large system sizes and long time scales, 
at the expense of atomic-scale accuracy. At the largest size and time 
scale, continuum methods enable one to simulate a wide range of 
dynamical processes, which can be compared directly to experi-
ments. 
The advances on computational methods aimed at the predic-
tion and understanding of falcipain structures, enzyme-inhibitor 
interactions, enzyme mechanism and inhibitors reactivity are sum-
marized below and organized according to the technique used in the 
reviewed studies. 
4.2. Homology Modeling 
The lack of an experimentally determined structure of a target 
protein frequently limits the application of structure-based drug 
design methods. X-ray crystallography continues to be an important 
source of high-resolution information on protein 3D structure. Un-
fortunately, there is often a considerable delay between determining 
the sequence of a protein and solving its 3D structure. Such delay is 
generally associated to difficulties in protein expression and, more 
commonly, in protein crystallization. In the absence of such crystal 
structures, sequence-based homology modeling is a well accepted 
alternative to derive tridimensional information for use in structure-
based drug design [110]. It was found that the performance of the 
homology model-based docking is comparable to that of the crystal 
structure-based docking, as long as sequence homology between 
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Fig. (9). Molecular structures of peptidomimetic and nonpeptidic falcipain inhibitors. 
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target and model proteins, in the binding site area, is over 50% 
[111]. 
Though the primary sequence of falcipains has been known for 
eight years, it was only four years ago that the first crystallographic 
structure was solved. In between, homology modeling was used as 
an important tool to derive falcipain 3D structures. Homology mod-
els of FP2 and FP3 were derived based on multiple sequence 
alignment (Fig. 10) of these enzymes sequence with homologs, 
such as the cysteine protease from Trypanosoma cruzi (cruzain) and 
the cysteine protease from Leishmania donovani, sharing more than 
40% homology in the mature domain and about 90% for the bind-
ing site residues [80, 95]. The rational structures of FP2 and FP3 
were developed by several groups [26, 89, 112, 113], validated by 
various structure/geometry verification tools, docking studies and 
site-directed mutagenesis and used in subsequent structured-based 
drug design studies. 
So far, six P. falciparum cysteine protease structures have been 
deposited in the Protein Data Bank. One of the structures (PDB 
code: 2GHU [114]) corresponds to the free FP2, three others con-
tain FP2 in complex with cystatin, chagasin and epoxysuccinate E-
64 (PDB codes: 1YVB [92], 2OUL [115] and 3BPF [116], respec-
tively) and the two remaining experimental structures represent FP3 
in complex with aldehyde leupeptin and K11017, a known potent 
vinyl sulfone inhibitor (PDB codes: 3BPM [116] and 3BWK [117], 
respectively). 
As mentioned above, falcipains possess two unique structural 
features: a “nose-like” projection connecting the L and R domains 
and an “arm-like” structure extending away from the protease sur-
face (Fig. 4). FPnose was found to be essential for the correct folding 
of the protein and subsequent gain of catalytic activity while FParm 
is required for hemoglobinase activity. These two motifs were al-
ready observed in the rational falcipain models but modeling analy-
ses of those structures did not identify mechanistic or functional 
roles for these sequence motifs because of the uncertainties in their 
conformations [89, 113]. However, structural analyses of the first 
FP2 experimental structure [92] revealed that FP2nose has, in fact, a 
short but significant element of secondary structure, and that a resi-
due in the protein core (GLU120) forms a buried hydrogen bond 
with TYR13 and a salt bridge with ARG5, two residues from 
FP2nose. These interactions may provide the additional binding en-
ergy necessary to stabilize initial interactions for folding. FParm, the 
second element unique to the FPs, is a jutting arm-like structure of 
two extended beta strands connected by an abrupt turn. Structural 
analysis found a negative charge clustering surrounding FParm and 
that the majority of this unique motif is distantly located from the 
active site. This suggests that FParm participates in hemoglobin deg-
radation through distal-site binding rather than direct participation 
in substrate cleavage. 
Despite the publication of the experimental structures for FP2 
and FP3, homology modeling remains a valuable tool for studies of 
the pro-domain of these enzymes. One of the common features that 
falcipains share with other papain-family cysteine proteases in-
cludes a prodomain with potent enzyme activity. Thus, several re-
searchers are interested in evaluating the features of FPs prodomain 
that mediate enzyme inhibition [118, 119]. However, the only ex-
perimental structures available for FPs are related to the mature 
proteolytic enzyme. So, models have to be constructed, in order to 
obtain structural information relative to the prodomain.  
Pandey, K. C. et al. [119] constructed a structure model of pro-
FP2 by homology modeling based on crystallographic structures of 
mature FP2, procathepsin-K, procathepsin-L and procaricain, offer-
ing insights into the nature of the interaction between the prodo-
main and mature domain of FP2 as well as into the broad specificity 
of inhibitory activity of the FP2 prodomain. They hypothesized that 
the inhibitory function is mediated by the dowstream portion of the 
prodomain, which has amino acid sequence similar to that of other 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). Sequence alignments of falcipain-2 and falcipain-3 with some homologs of the cysteine protease family used in homology modeling studies. Resi-
dues inside boxes represent the structurally conserved regions. Text within parentheses corresponds to the PDB code of the protein. Only the mature sequence 
of falcipains is presented here. Adapted from [26]. 
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papain family proteases. These two conserved regions correspond 
to a sequence of 6 (ERFNIN) and 4 (GNFD) amino acids (Fig. 11). 
The pro-FP2 model identified potential interactions between the 
inhibitory portion of the prodomain and mature falcipain-2 that 
stabilize the overall fold and appear to explain inhibitory activity. 
Such interactions correspond to: i) a salt-bridge between ARG185 
and GLU121, ii) another salt-bridge between GLU210 (from 
GNFD) and LYS403 in the mature domain, iii) apolar contacts and 
-bond stacking between PHE214 with TRP449 and TRP453 on the 
mature domain. 
4.3. Docking Studies 
The goal of most molecular docking methods is to predict the 
binding mode of a small molecule to a macromolecular receptor. 
The docking problem can be split into two different components. 
These are the generation of conformations (searching algorithms) of 
the receptor–ligand complex and scoring function to discriminate 
between the correct and wrong binding poses [120]. The ensemble 
of generated conformations must be sufficiently large to contain the 
best structure that represents the receptor–ligand complex and the 
scoring function should be able to assign the best score to this con-
formation. Examples of available docking programs are GOLD 
[121, 122], GLIDE [123, 124], DOCK [125], and AutoDock [126].  
When the 3D structure of a drug target is available, docking 
methods have two main applications: i) virtual High Throughput 
Screening (vHTS) and ii) structural information. vHTS consists in 
the use of docking methods to screen compound libraries in silico to 
rank the compounds regarding their binding affinities to the target 
receptor and, ultimately, get the so-called hit(s), i.e., predictably 
high-affinity compound(s). This way, the huge costs and time con-
sumptions associated to lead discovery by conventional experimen-
tal (“wet”) High Throughput Screening can be dramatically re-
duced. Besides, the structural information from the theoretically 
modeled complex may help to clarify the catalytic mechanism of 
enzyme and to tailor novel highly potent enzyme inhibitors. As 
stated above, in recent years, researchers are devoting many efforts 
in searching FPs inhibitors, but not all structures of inhibitor(s)-
FP(s) complexes are available. So, to understand the interaction 
mode between inhibitors and FPs, knowledge about the structures 
of the complexes is a necessary condition that can be reached with 
docking methods. 
4.3.1. Virtual Screening 
We have seen that the majority of FPs inhibitors correspond to 
peptide-based or peptidomimetic compounds. However, these com-
pounds are subjected to metabolic degradation. Thus, it would be of 
great interest to discover non-peptide inhibitors, which are less 
exposed to degradation by host proteases and, thereby, more likely 
to offer in vivo activity. One of the strategies to search for such 
compounds is the use of virtual screening, which has emerged as a 
powerful tool for identification of novel and diverse leads [127, 
128]. Relative to the discovery of falcipain inhibitors, three virtual 
screening studies should be highlighted. 
Two of them were made by Desai, P.V. et al. who used models 
of FP2 and FP3 issued from homology modeling to screen the 
ChemBridge Database [129] and the Available Chemical Directory 
[130] with 241000 and 355000 compounds, respectively. Firstly, 
the databases were filtered to collect only druglike molecules. Thus, 
compounds with metals were removed and, in the case of salts, the 
counterions were stripped and the anions were neutralized. The 
remaining molecules were then filtered based on ADME parame-
ters, and finally subjected to the Lipinski’s rule of five [131]. The 
filtered ChemBridge Database and the Available Chemical Direc-
tory consisted of approximately 60000 and 80000, respectively. 
After that, the GOLD software [122] was utilized to screen the 
molecules applying a docking protocol, which was previously es-
tablished by a docking study carried out with the crystal structure of 
cruzain and a vinyl sulfone inhibitor. 
The top 200 common hits for the two FPs were inspected based 
on several criteria: i) reasonable internal energy of the ligand in the 
binding pose, ii) proximity of the electrophilic center of the ligand 
(if any present) to the catalytic cysteine and iii) complementary 
between the ligand and protein surfaces in terms of spatial occu-
pancy and hydrophilic/hydrophobic regions. In the case of the 
ChemBridge Database, 22 compounds appeared to inhibit either or 
both of the enzymes with IC50 values ranging from 1 to 63 M, 
with 12 compounds showing dual activity. Relative to the Available 
Chemical Directory, 18 compounds were found to be low micromo-
lar inhibitors of FP2 and/or FP3 and, among these molecules, seven 
showed to have dual activity. All of the ligands seemed to have 
reasonable interactions and shape complementarity to the active site 
of the enzyme. Six of the most active compounds issued from these 
studies are summarized in Table 2. 
Despite all selected compounds appeared to span the four major 
subsites of the binding pockets, S1, S1’, S2 and S3, subtle differ-
ences could be observed in specific interactions. The analysis of the 
docked binding conformation of compound 2 (Table 2) revealed 
that the molecule forms strong van der Waals (vdW) interactions 
with the binding pocket residues and - stacking interactions with 
TRP206 in the S1’ pocket. Additionally, the carboxylate groups of 
the inhibitor accept H bonds from the backbone amide proton of 
ILE85 in the S2 pocket.  
Although most other inhibitors also appeared to form one or 
more H bonds with the S1’ cavity residues, other molecules showed 
additional interactions with the S3 pocket, but other significant 
interactions with the S1’ pocket were not found. On the other hand, 
some compounds showed to have fewer interactions with the S3 
pocket than those with the S1 cavity. But, in the end, all ligands 
presenting good activity against FP2 and/or FP3 seemed to have 
reasonable interactions with the S2 pocket, which are thought to be 
major determinants of specificity for this class of cysteine proteases 
[130]. 
The third virtual screening study reported so far was performed 
by Li, H. et al. being the first published example where a crystal 
structure of FP2 was used for virtual screening [132]. Indeed, the 
experimental structure (PDB code: 2GHU) was employed to search 
the SPECS database (http://www.specs.net) for novel nonpeptidic 
FP2 inhibitors. Since different docking programs with various scor-
ing functions are known to emphasize different aspects of ligands, 
  
 
 
 
 
 
Fig. (11). Schematic representation of the domains of falcipains. Cyto: cytolsolic domain; TM: transmembrane domain; Hb: hemoglobin. ERFNIN and GNFD 
represent the one-letter code of the peptide sequence. Adapted from [119]. 
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the authors opted to screen the database with two different docking 
softwares: Glide [124] and GAsDock [133]. 
The almost 278000 compounds in the SPECS database were re-
duced, after applying a druglike filter, to about 80000, which were 
subsequently ranked and docked with the two docking programs. 
After visual inspection of the top 200 molecules obtained with each 
program, 53 and 56 compounds were finally selected by Glide and 
GAsDock, respectively. From these final molecules only one was 
common to the two docking programs, which confirmed that differ-
ent scoring functions indeed emphasize different aspects of ligands. 
Table 3 registers the three most active compounds reported from 
this work. 
The predicted binding poses of the inhibitors revealed that most 
of them span and occupy the S2 and S1’ pockets with no significant 
interactions with the S1 cavity. It was also observed that the se-
lected inhibitors form mostly vdW and hydrophobic interactions 
with GLY83, ILE85 and ALA235 (in S2 cavity) and, in particular, 
with VAL152 (in S1’ subsite), which can explain why additional 
lipophilic substituents seem to give better occupancy. In addition, 
the authors found that some compounds established - stacking 
interactions between their aromatic systems and TRP206, in the S1’ 
pocket, which appeared to be a necessary feature for good activity. 
Finally, it was pointed out that the central saddle linker, which con-
nects compound moieties binding to S2 and S1’ pockets, tend to 
form H bonds with the polar residues around the active site, such as 
ASN173, HIS172 and TRP206. 
It should be noted that the inhibitors identified by virtual 
screening have generally IC50 values in the micromolar range, and 
thus may not be suitable for use as drugs themselves but constitute 
Table 2. Inhibitory Activities of some Compounds Issued from Virtual Screening Against FP2 and FP3 
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novel and diverse lead structures that should be pursued in lead 
optimization studies. 
4.3.2. Structural and Functional Properties of Falcipain-Inhibitor 
Complexes 
As mentioned above, the docking technique also serves to re-
trieve structural information from the theoretically modeled com-
plexes when these are not available experimentally. These studies 
represent the major theoretical works developed for falcipains in-
hibitors and some of them are reviewed below. 
One of the first studies that applied structure-based drug design 
methods to falcipain inhibitors development was entailed by Ring, 
C.S., et al. [112]. After identifying oxalic bis[(2-hydroxy-1-napht-
hylmethylene)hydrazide] (Fig. 12) as a nonpeptidic inhibitor of the 
malarial cysteine protease, the analysis of the docking-generated 
enzyme-inhibitor complex provided structural information on bind-
ing between the molecule and the target receptor. The hydrophobic 
site S2 was found to be filled by one naphtol group, while the other 
naphtol group participates in a - stacking interaction with the 
indole of TRP177 at the S1’ pocket. Also, each of the hydroxyl 
groups in the naphtol rings were seen to establish H bonds with 
SER160 and GLN19 at the S2 and S1’ cavities, respectively. 
Sabnis, Y.A., et al. [26], built a homology model of FP3 and 
compared it to a previously reported homology model of FP2. The 
results of this study showed that, despite the active site of the two 
cysteine proteases is generally conserved, significant differences 
observed might lead to diverse ligand specificity. Some major al-
terations in the S2 pocket were detected such as two leucine amino 
acids in FP2, LEU84 and LEU172, that are replaced by TYR86 and 
PRO174, respectively, in FP3. These bulkier tyrosine and proline 
residues in FP3 induce an important steric difference between S2 
cavities, which lead to a narrower S2 pocket in FP3 and could ex-
plain trends of lower experimentally inhibitory activities of various 
substrates with FP3, as compared to FP2 [80]. In order to find if this 
difference could significantly affect ligand interactions, the authors 
compared the best docking mode of Z-Phe-Arg-AMC (Fig. 13) with 
the two cysteinases.  
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Fig. (12). Molecular structure of oxalic bis[(2-hydroxy-1-naphthyl-
methylene)hydrazide]. 
They noticed that the compound binds to the enzymes in a simi-
lar conformation, with the distance between sulphur of catalytic 
CYS and the point of cleavage of the substrate (carbonyl carbon of 
arginine) in the range of 3-4 Å. However, the position of the benzy-
loxycarbonyl group (Z) was found to be different in the two falci-
pains. In FP2, this group fits into the S2 pocket along with the 
phenyl group, whereas in FP3 it is dislocated away from the center 
of the S2 cavity. This displacement appeared to be mainly due to 
the narrower S2 pocket of FP3. 
Table 3. Inhibitories Activities of some Compounds Issued from a Virtual Screening Study Against FP2 
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Fig. (13). Molecular structure of N--benzyloxycarbonyl-L-phenylalanyl-L-
arginine-7-amino-4-methylcoumarin (Z-Phe-Arg-AMC). 
In another study performed by Batra, S., et al. [96], a homology 
model of FP2 was used to design a new nonpeptidic inhibitor hav-
ing an isoquinoline motif (Fig. 14a). Chemical synthesis and assay 
for inhibition of the cysteine protease revealed this molecule to be 
active in the M range. The interaction established between the 1-
(4-hydroxy-phenyl) group of the ligand and ASP234 in the S2 
pocket was considered essential. Therefore, in order to discover 
new antimalarial agents, the authors decided to synthesize and 
evaluate simpler 1,6,7-trisubstituted isoquinoline analogues (Fig. 
14b). The analysis of the inhibitor-enzyme complexes issued from 
docking suggested that the S2 pocket prefers to accommodate hy-
drophobic groups, since more and stronger interactions were found 
for molecules bearing the p-benzyloxy phenyl group, as compared 
to their corresponding hydroxyl analogues. 
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Fig. (14). Representative structure of a) isoquinoline motif and b) 1,6,7-
trisubstituted isoquinoline analogues. 
In a work of Goh L. L. and co-workers [82, 89], computational 
approaches, such as sequence alignment and homology modeling of 
FP2, were used to identify clusters of residues unique to the parasite 
protease that can be targeted for drug design. In addition to the 
catalytic triad, (CYS42, HIS174 and ASN204 in FP2) the residues 
SER149, ILE85, ALA151, ASP155, CYS99 and CYS119 were 
found to be strictly conserved between FPs when compared to hu-
man cathepsins. Thus, these differences in substrate binding sites 
may be exploited to the drug design of specific falcipain inhibitors. 
Structural analysis showed that SER149, ILE85, ALA151 and 
ASP155 do not participate directly in the catalytic reaction, but 
enhance substrate bond alignment with the catalytic amino acids. 
This was confirmed by site-directed mutagenesis, since removal of 
the serine side chain hydroxyl (S149A mutant) resulted in signifi-
cant loss of proteolytic activity against some peptide substrates. 
Likewise, simultaneous substitution of the neighboring amino acids 
ILE85 and ALA151 presented an additive effect over the single 
mutant and rendered the double mutants completely inactive against 
the peptide substrates. These three residues were observed to be 
located in the hydrophobic cleft of the active center, suggesting that 
they may play important roles in substrate binding and specificity, 
namely establishing hydrophobic interactions with peptide sub-
strates. On the other hand, ASP155 was shown to be less essential 
for substrate recognition/binding since the mutant D155A displayed 
a 50% decrease in activity relative to the wild-type enzyme. Re-
garding amino acids CYS99 and CYS119, these residues were 
found to be absent in the human cysteinase analogues. Although 
observation of the homology model of FP2 revealed that these CYS 
residues do not form part of the active site, their conserved nature in 
FPs suggests that they have an important role. Structural analysis 
showed that the conformational modifications that these amino 
acids induce at the protease amino-terminal segment indirectly 
influence the folding of FP2 and, consequently, the active confor-
mation of the protease. 
The homology structures of FP2 and FP3 were also used in the 
structure-based design of novel trialkyl-substituted thiazoles per-
formed by Goud, P. M., et al. [134]. The authors chose the thiazole 
ring as core in this series because of the resulting spatial arrange-
ment of the three alkyl groups, which is thought to allow the forma-
tion of key interactions with the amino acids in the active site (Fig. 
15). The fact that the thiazole ring is bioavailable and, as previously 
reported, that it mimics the amino acid portion of a peptide bond if 
held in a planar arrangement, also motivated the authors to select 
this heterocycle as a common motif for this family of FP non-
peptide inhibitors [134]. 
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Fig. (15). Proposed schematic representation of important interactions be-
tween designed thiazole inhibitors and falcipain amino acids. Hydrogen 
bonds are shown in dotted lines. Residues are numbered for FP2. Adapted 
from [134]. 
From this modeling study resulted a series of thiazole analogues 
conceived in order to mimic important interactions exhibited by 
known inhibitors (Fig. 15), and which were docked into the model 
structures of FP2 and FP3. Some representative structures of the 
designed thiazoles are shown in Fig. (16). 
The binding mode of the designed thiazoles showed that they 
are able to form a tetrahedral intermediate with CYS42 and to es-
tablish H bonds with key catalytic residues of the enzyme. The 
COCH2X group of the inhibitors interacts with the thiolate/ imida-
zolium ion pair of FPs wherein the carbonyl oxygen of the com-
pounds is involved in H bonds with the amide proton of the cata-
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lytic cysteine, and with the side chain amide protons of GLN36 in 
the oxyanion hole. The phenyl group interacts with the S3 pocket 
mainly by hydrophobic contacts. Moreover, the side chain hydroxyl 
or the amide protons at position 4 or 5 of the thiazole ring appear to 
form a H bond with either the ASP234 side chain or SER149 in the 
S2 cavity. 
More recently, another modeling study was performed by 
Veríssimo, E. et al. [107], who derived falcipain inhibitors present-
ing a non-peptidic scaffold that could constrain the amino acid 
backbone. This way, the molecules would have some advantages, 
such as improved selectivity by stabilizing a biologically active 
conformation and consequent decreased toxicity to the human host. 
Several molecules presenting a common 2-pyridone motif (Fig. 17), 
different P1 fragments for recognition and binding to the enzyme, 
and different Michael acceptor groups capable of reacting with the 
thiolate of cysteine residue, were designed, synthesized and evalu-
ated for their inhibitory activity against falcipains. 
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Fig. (17). Molecular structure of 2-pyridone derivatives. 
The results confirmed that P1 recognition sites of FP2 inhibitors 
exhibiting longer chain substituents performed much better. Despite 
modeling studies showed good matches between peptidomimetic 
conformations and their peptidic counterparts, antimalarial activity 
is more significant in the case of the vinyl sulfone analogues, sug-
gesting that the electrophilic moiety of the latter is very reactive 
towards the nucleophilic thiolate group of FPs. 
4.4. Molecular Dynamics 
As mentioned above, MD is a statistical mechanics method in 
which the time evolution of interacting atoms is followed by inte-
grating their equations of motion. Classical MD relies on Molecular 
Mechanics (MM) to simulate the deformations, movements and 
interactions of molecules, which in turn allow the calculation of 
energetic, thermodynamic, structural and dynamic properties as 
well as conformational searches. 
Cieplak, P. and co-workers [135] performed one of the first and 
few MD studies on model complexes of FPs inhibitors. In their 
work, classical MD was used as a filter for evaluating proposed 
binding modes. In addition, they calculated free energy derivatives 
at each atom of the molecules. From their results it was possible to 
suggest which atomic regions should have larger or smaller van der 
Waals radii, larger or smaller van der Waals well depths and larger 
or smaller partial charges. This computational approach was applied 
to three compounds (Fig. 18). The first compound, oxalic-bis-(2-
hydroxy-1-naphtylmethylene)-hydrazide, was issued from a virtual 
screening study. The second molecule was obtained from the latter 
by introducing a shorter linker between the aromatic rings, in order 
to have the ability to move more freely along the enzymatic side of 
the protein. Finally, the third species selected for the test was 
ZLIV114A, the best tri-aryl inhibitor found in a screening previ-
ously performed by Li, Z., et al. [136]. 
After minimization, equilibration and 100 ps of MD production, 
all molecules were found to be close to their initial docked posi-
tions, with largest atomic displacements found to be ~4 Å. Impor-
tantly, the electrostatic contribution of the free energy derivatives 
suggested that binding improvements to the enzyme should be 
based on the increment of both size and electropositive character of 
the aryl ring located close to the S2 subsite, whereas binding to the 
cysteine protease should be focused in the insertion of more elec-
tronegative groups into the aryl ring positioned in the S1’ pocket. 
4.5. Quantum Mechanical Methods 
Although not directly resulting in new inhibitors, quantum me-
chanics (QM) and/or combined quantum mechanics / molecular 
mechanics (QM/MM) methods have given important insights into 
the catalytic mechanism of falcipains and into the falcipain inhibi-
tors reactivity. QM approaches are mandatory for the computation 
of bond-breaking or bond-forming processes but, on the other hand, 
large systems such as protein-ligand complexes would be prohibi-
tively expensive – in terms of computational resources - if fully 
treated by quantum mechanics. Therefore, combined QM/MM 
methods are frequently used to treat, at different levels of calcula-
tion, various regions of the systems under study.  
Concerning the application of QM or QM/MM approaches to 
the scrutiny of FPs inhibitors, many examples are focused on epox-
ides and aziridines [137-141]. 
Kinetics, thermodynamics and regioselectivity of the ring-
opening reaction of epoxide- and aziridine-based agents (Fig. 19) 
has been investigated by QM calculations [138, 139]. Generally, the 
mode of action of these molecules is described as a two-step 
mechanism. Firstly, there is a formation of a non-convalent en-
zyme-inhibitor complex assured by a favorable arrangement of the 
molecule into the binding pocket. Then, ring opening (Fig. 20) 
takes place, when one of the carbon atoms of the ring is attacked by 
the thiolate group of the catalytic CYS, which leads to irreversible 
alkylation of this amino acid. 
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Fig. (16). Representative structure of designed thiazole derivatives as FP inhibitors. 
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Fig. (19). General structure of (a) epoxide- and (b) aziridine-based  
inhibitors. 
The quantum chemical calculations predicted that protonation 
of the nitrogen center of aziridine-based inhibitors occurs at the 
beginning of the reaction course, more precisely, prior to the transi-
tion state for the ring opening described above. Importantly, it was 
found also that, without such previous N-protonation step, the az-
iridine is not active. Therefore, it is suggested that the protonation 
stabilizes both the transition state and the product of ring opening, 
significantly increasing the reaction rate. Hence, electron-
withdrawing substituents at the nitrogen atom should lead to lower 
reaction barriers and, consequently, to higher inhibition potencies. 
For epoxide-based inhibitors, the protonation of the oxygen center 
takes place only after occurrence of the transition state; therefore, 
since the products are strongly stabilized, only the thermodynamics 
of this reaction is favored by the O-protonation, while the kinetics 
remains unchanged, in contrast with the behavior of aziridines. 
Keeping in mind that N-substituted aziridine-based derivatives 
are more potent than the corresponding N-unsubstituted analogues, 
Buback, V. et al. focused on the N-substitution pattern by varying 
the electron-withdrawing power of substituents like CHO, Cl, Br, 
CF3, CF2H and C6H4NO2 [137]. Insights into the kinetics and ther-
modynamics of ring opening were obtained for the different N-
substituted aziridines (Fig. 21), through the achievement of two-
dimensional potential energy surfaces, and compared with the cor-
responding non-substituted analogues. The computed reaction bar-
riers for the substituted aziridines ranged from 13-16 kcal·mol
-1
, 
representing a decrease in the activation barriers of up to 15 
kcal·mol
-1
, as compared to the unsubstituted compounds, supporting 
the correlation between compound activity and the presence of such 
groups attached to the N atom.  
Relevantly, this study provided further evidence that the inhibi-
tory activity of the tested heterocyclic molecules is also due to a 
nucleophilic attack of the CYS thiolate to an electron-deficient 
carbon of the inhibitor, in this particular case involving concomitant 
opening of the inhibitor’s ring structure. The only exception was 
observed for N-formyl-aziridines, which display other reaction 
pathways (e.g., attack at the carbonyl carbon) that may be involved 
in the inhibition mechanism as already reported in a previous work 
[141]. 
In another example, QM/MM methods were applied to investi-
gate the importance of the HIS residue present at the FPs active site 
for the activity of epoxide- or aziridine-based cysteine proteases 
inhibitors [140]. The results excluded a direct proton shift from HIS 
to the organic ligand, showing instead that a single water molecule 
is sufficient to establish a very efficient relay system, which turns 
easier the proton transfer from HIS to the inhibitor. This finding 
strongly suggests that substituents susceptible to block the proton 
transfer might diminish the activity of the inhibitors. 
Regarding the use of semi-empirical methods in the study of 
potential FPs inhibitors, Sant’Anna et al. performed calculations on 
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Fig. (20). Schematic representation of the ring opening mechanism of the alkylation of a methyl thiolate by an N-substituted aziridine ring. Adapted from 
[137]. 
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a series of acylhydrazones (Fig. 22) at the AM1 level [142]. These 
acylhydrazones, which were found to inhibit cysteinases at the nM 
level, resulted from lead optimization studies based on the oxalic 
bis[(2-hydroxy-1-naphtylmethylene)hydrazide] originally reported 
by Ring and co-workers [112].  
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Fig. (21). Molecular structure of N-substituted aziridines. 
 
R1 = H, OMe
R2 = H, OH, OMe, Cl
R3 = H, OH, OMe, Cl
R4 = H, OH
R3
R2
R1 R4
H N
N
H
O
N
N
 
Fig. (22). Molecular structures of pyrazole acylhydrazones. 
According to the work by Sant’Anna et al. the AM1-derived 
heats of formation for the (Z)- and (E)-isomers of the acyl-
hydrazones were found to be very similar. Also, the calculated 
atomic charges (based on Mulliken populations) suggested that a 
more positive charge in the amide carbonyl, which is to be attacked 
by the catalytic CYS, tends to favor the formation of the tetrahedral 
intermediate.  
In addition, the pyrazole ring and the oxygen atom from the hy-
droxy and/or methoxy moities of the aromatic ring, were found to 
establish important stabilizing contacts (hydrogen bonds) with the 
active site amino acids. 
Lastly, it should be outlined that QM/MM methods are quite 
time demanding on both preparing the system and subsequent cal-
culations; therefore, their application in the accurate molecular 
description of the active site in enzyme-inhibitor complexes is quite 
limited. Nevertheless, recent advances in computational facilities 
allow foreseeing that these approaches will turn practical in the near 
future, hopefully facilitating the accomplishment of atomically 
detailed mechanistic studies of plasmodial cysteine proteases, as 
well as the attainment of reactivity insights into other typical FP 
inhibitor classes such as that of vinyl sulfones. 
CONCLUDING REMARKS 
The increasing resistance of Plasmodium parasites to conven-
tional drug therapy, the inexistence of a vaccine and the appearing 
of insecticide-resistant mosquitoes make malaria a worldwide pub-
lic health threat. Thus, the existing situation clearly suggests an 
urgent need for development of new potent, mechanism-based an-
timalarial agents. During the last two decades, we have witnessed 
an impressive scientific effort to discover new targets for antimalar-
ial therapy, and among them, the falcipain family proteases, namely 
FP2 and FP3, have been defined as promising drug targets. In the 
present review, several molecular modeling tools used in the identi-
fication of new falcipain inhibitors and lead optimization were 
overviewed. One of the major computational approaches employed 
in the development of FPs inhibitors consists of the establishment 
of falcipain structures by homology modeling. The availability of 
such structural information, combined with docking, is likely to 
increase the success of virtual screening and of structural and func-
tional properties of falcipain-inhibitor complexes. More recently, 
some mechanistic studies were also reported, which have not re-
sulted directly in the designg of new drugs, but gave important 
insights into the catalytic mechanism of falcipains and into the reac-
tivity of falcipains inhibitors. In conclusion, the discussed efforts 
towards the design of inhibitors of the malarial cysteine proteases 
clearly demonstrate the effectiveness of combining computational 
techniques with organic synthesis in delivering novel potential in-
hibitors and in providing directions for further improvements. 
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